查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1584636

全球肺動脈高血壓（PAH）治療市場：依藥物類型、給藥途徑、通路、地區、趨勢分析、競爭格局、預測，2019-2030年

Pulmonary Arterial Hypertension Treatment Market, By Drug Type; By Route of Administration; By Distribution Channel; By Region, Global Trend Analysis, Competitive Landscape & Forecast, 2019-2030
出版日期: | 出版商: Blueweave Consulting | 英文 448 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

到 2030 年，全球肺動脈高血壓(PAH) 治療市場規模將達到 103 億美元

由於肺動脈高壓盛行率的上升、藥物開發的進步、對該疾病的認知不斷提高、醫療保健基礎設施的改善以及對有效治療方法的需求不斷成長，全球肺動脈高血壓（PAH）治療市場預計將不斷成長。 。

領先的策略諮詢和市場研究公司 BlueWeave Consulting 在最近的一項研究中估計，2023 年肺動脈高血壓(PAH) 治療的全球市場規模將達到 75 億美元。 BlueWeave 預測，2024-2030 年期間，全球肺動脈高血壓（PAH）治療市場規模將以 4.80% 的複合年成長率成長，到 2030 年達到 102.8 億美元。全球肺動脈高血壓(PAH) 治療市場是由 PAH 盛行率上升、對該疾病認知的提高以及標靶治療的進步所推動的。醫療費用的增加、老年人口的增加以及藥物聯合治療市場的開拓將進一步支持市場成長。此外，內皮素受體拮抗劑 (ERA)、磷酸二酯酶 5 抑制劑 (PDE-5i) 和前列腺環素類似物等新型藥物的出現極大地擴展了治療選擇並改善了患者預後，這導致了疾病的改善，並成為市場的驅動力。

機會 -聯合治療的開發和採用

擴大採用聯合治療是全球肺動脈高血壓（PAH）治療市場的主要促進因素。結合不同的藥物類別，包括內皮素受體拮抗劑 (ERAs)、磷酸二酯酶 5 抑制劑 (PDE5Is) 和前列腺環素素類似物，可以透過針對多種疾病途徑來改善患者的治療效果。醫療保健提供者擴大採用這些療法，因為它們可以提高治療效果、減緩疾病進展並降低死亡率，從而推動市場成長。

地緣政治緊張局勢加劇對全球肺動脈高血壓（PAH）治療市場的影響

地緣政治緊張局勢加劇可能會影響供應鏈，導致藥物短缺，並因受影響地區的不穩定性而推遲臨床試驗，從而擾亂全球肺動脈高血壓（PAH）治療市場。關稅、制裁和貿易限制的增加可能會增加藥品的生產和分銷成本，並限制其在某些市場的供應。此外，經濟不穩定和政府優先事項的變化可能會導致醫療保健資金流失，特別是在脆弱和新興經濟體，可能會影響多環芳烴研究投資、治療成本和整體患者照護。

北美引領全球多環芳烴治療市場

北美主導全球肺動脈高血壓（PAH）治療市場。北美的主導地位歸因於該地區先進的醫療基礎設施、對 PAH 的高度認知以及易於獲得的治療選擇。此外，PAH 在美國的盛行率很高。對新治療方法研發計劃的大力投資支持了該地區的市場領導地位。該地區（尤其是美國）擁有世界領先的製藥公司，使該地區在歐洲、亞太地區、拉丁美洲和中東地區的全球肺動脈高血壓治療（PAH）市場中處於關鍵地位。

競爭格局

全球肺動脈高血壓（PAH）治療市場競爭激烈，許多公司爭奪更大的市場佔有率。市場主要企業包括United Therapeutics Ltd、拜耳AG、Actelion Ltd、輝瑞公司、吉利德科學公司、葛蘭素史克公司、梯瓦製藥公司、禮來公司、Steady Med Ltd、Viatris Inc、Sandoz Inc、Lupin Pharmaceuticals 、 Inc.、太陽製藥工業公司和強生公司。這些公司正在增加對研發活動、併購、合資、聯盟、授權合約、新產品和服務的投資，以進一步鞏固其在全球肺動脈高血壓（PAH）治療市場的地位。

該報告的詳細分析提供了有關全球肺動脈高血壓（PAH）治療市場的成長潛力、未來趨勢和統計數據的資訊。它還重點關注推動市場總規模預測的因素。該報告致力於提供全球肺動脈高血壓（PAH）治療市場的最新技術趨勢以及產業見解，以幫助決策者做出明智的策略決策。此外，我們也分析了市場的成長動力、挑戰和競爭力。

目錄

第1章 研究框架

第 2 章執行摘要

第3章全球肺動脈高血壓（PAH）治療市場洞察

  • 分銷通路價值鏈分析
  • DROC分析
    • 生長促進因子
      • 肺動脈高壓盛行率增加
      • 治療進展
      • 醫療費用增加
    • 抑制因素
      • 治療費用高
      • 部分地區認知不足
      • 獲得專業醫療護理的機會有限
    • 機會
      • 個人化醫療的進展
      • 聯合治療的發展
      • 對數位健康解決方案的需求增加
    • 任務
      • 開發和核准新的多環芳烴治療方法的監管障礙
      • 獲得 PAH 治療報銷
  • 科技進步/最新趨勢
  • 法律規範
  • 波特五力分析

第4章全球肺動脈高血壓（PAH）治療市場：行銷策略

第5章全球肺動脈高血壓（PAH）治療市場：價格分析

第6章全球肺動脈高血壓（PAH）治療市場：區域分析

  • 全球肺動脈高血壓(PAH) 治療市場，區域分析，2023 年
  • 2024-2030年全球肺動脈高血壓（PAH）治療市場吸引力分析

第7章全球肺動脈高血壓（PAH）治療市場概述

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 依藥物類型
      • 內皮素受體拮抗劑（ERA）
      • 磷酸二酯酶 5 (PDE-5) 抑制劑
      • 前列腺環素類似物
      • 可溶性鳥苷酸環化酶促效劑
      • 其他
    • 依給藥途徑
      • 口服
      • 靜脈
      • 皮下的
      • 吸入
    • 按分銷管道
      • 醫院藥房
      • 零售藥房
      • 網路藥房
    • 按地區
      • 北美洲
      • 歐洲
      • 亞太地區 (APAC)
      • 拉丁美洲 (LATAM)
      • 中東和非洲 (MEA)

第8章北美肺動脈高血壓（PAH）治療市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 依藥物類型
    • 依給藥途徑
    • 按分銷管道
    • 按國家/地區
      • 美國
      • 加拿大

第9章歐洲肺動脈高血壓（PAH）治療市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 依藥物類型
    • 依給藥途徑
    • 按分銷管道
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 其他歐洲國家

第10章亞太肺動脈高血壓（PAH）治療市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 依藥物類型
    • 依給藥途徑
    • 按分銷管道
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲和紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 越南
      • 亞太地區其他地區

第11章拉丁美洲肺動脈高血壓（PAH）治療市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 依藥物類型
    • 依給藥途徑
    • 按分銷管道
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 其他拉丁美洲

第12章中東與非洲肺動脈高血壓（PAH）治療市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 依藥物類型
    • 依給藥途徑
    • 按分銷管道
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • 其他中東/非洲

第13章競爭格局

  • 主要參與者及其產品列表
  • 2023年全球肺動脈高血壓（PAH）治療公司市場佔有率分析
  • 透過管理參數進行競爭基準基準化分析
  • 重大策略發展（合併、收購、聯盟等）

第14章地緣政治緊張局勢加劇對全球肺動脈高血壓（PAH）治療市場的影響

第15章 公司簡介（公司簡介、財務矩陣、競爭格局、關鍵人員、主要競爭對手、聯絡方式、策略展望、SWOT分析）

  • United Therapeutics Ltd
  • Bayer AG
  • Actelion Ltd
  • Pfizer, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Steady Med Ltd
  • Viatris Inc.
  • Sandoz Inc.
  • Lupin Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries, Inc.
  • Johnson &Johnson
  • 其他主要企業

第16章 主要策略建議

第17章調查方法

簡介目錄
Product Code: BWC24793

Global Pulmonary Arterial Hypertension (PAH) Treatment Market Size to Touch USD 10.3 Billion by 2030

Global Pulmonary Arterial Hypertension (PAH) Treatment Market is thriving due to a rising prevalence of pulmonary hypertension, advancements in drug development, increasing awareness about the disease, improving healthcare infrastructure, and growing demand for effective therapies.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Pulmonary Arterial Hypertension (PAH) Treatment Market size by value at USD 7.50 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Pulmonary Arterial Hypertension (PAH) Treatment Market size to expand at a CAGR of 4.80% reaching a value of USD 10.28 billion by 2030. Global Pulmonary Arterial Hypertension (PAH) Treatment Market is driven by rising prevalence of PAH, growing awareness about the condition, and advancements in targeted therapies. Increasing healthcare expenditure, a growing geriatric population, and the development of combination drug therapies further fuel market growth. Additionally, the availability of novel drugs such as endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE-5i), and prostacyclin analogs significantly enhances treatment options, leading to improved patient outcomes and driving market expansion.

Opportunity - Development and Adoption of Combination Therapies

Increasing adoption of combination therapies is a key driver in Global Pulmonary Arterial Hypertension (PAH) Treatment Market. Combining different drug classes, such as endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE5Is), and prostacyclin analogs, has shown improved patient outcomes by targeting multiple disease pathways. These therapies enhance treatment efficacy, slow disease progression, and reduce mortality rates, which encourages healthcare providers to adopt them, thereby boosting market growth.

Impact of Escalating Geopolitical Tensions on Global Pulmonary Arterial Hypertension (PAH) Treatment Market

Escalating geopolitical tensions could disrupt Global Pulmonary Arterial Hypertension (PAH) Treatment Market by impacting supply chains, causing drug shortages, and delaying clinical trials due to instability in affected regions. Increased tariffs, sanctions, and trade restrictions may raise production and distribution costs for medications, limiting accessibility in certain markets. Additionally, economic instability and shifting government priorities may divert healthcare funding, affecting investment in PAH research, treatment affordability, and overall patient care, particularly in vulnerable or developing economies.

North America Leads Global PAH Treatment Market

North America dominates Global Pulmonary Arterial Hypertension (PAH) Treatment Market. Leadership position of North America is due to the region's advanced healthcare infrastructure, higher awareness about PAH, and greater accessibility to treatment options. Additionally, a higher prevalence of PAH in United States. Strong investments in R&D programs for new therapies support the region's market leadership. The strong presence of major global pharmaceutical companies in the region, particularly in United States, further contributes to the region's significant position in Global Pulmonary Arterial Hypertension Treatment (PAH) Market among Europe, Asia Pacific, Latin America, and Middle East and Africa.

Competitive Landscape

Global Pulmonary Arterial Hypertension (PAH) Treatment Market is fiercely competitive, with numerous companies vying for a larger market share. Major companies in the market include United Therapeutics Ltd, Bayer AG, Actelion Ltd, Pfizer, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Teva Pharmaceuticals Inc., Eli Lilly and Company, Steady Med Ltd, Viatris Inc., Sandoz Inc., Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., and Johnson & Johnson. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global Pulmonary Arterial Hypertension (PAH) Treatment Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Pulmonary Arterial Hypertension (PAH) Treatment Market. It also highlights the factors driving forecasts of total Market size. The report promises to provide recent technological trends in Global Pulmonary Arterial Hypertension (PAH) Treatment Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the Market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Pulmonary Arterial Hypertension Treatment Market Insights

  • 3.1. Distribution Channel Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing prevalence of pulmonary arterial hypertension
      • 3.2.1.2. Advancements in treatment
      • 3.2.1.3. Rising healthcare spending
    • 3.2.2. Restraints
      • 3.2.2.1. High cost of treatments
      • 3.2.2.2. Lack of awareness in some regions
      • 3.2.2.3. Limited access to specialized care
    • 3.2.3. Opportunities
      • 3.2.3.1. Advances in personalized medicine
      • 3.2.3.2. Development of combination therapies
      • 3.2.3.3. Increasing demand for digital health solutions
    • 3.2.4. Challenges
      • 3.2.4.1. Regulatory hurdles for the development and approval of new PAH treatments
      • 3.2.4.2. Obtaining reimbursement for PAH treatments
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Pulmonary Arterial Hypertension Treatment Market: Marketing Strategies

5. Global Pulmonary Arterial Hypertension Treatment Market: Pricing Analysis

6. Global Pulmonary Arterial Hypertension Treatment Market: Geography Analysis

  • 6.1. Global Pulmonary Arterial Hypertension Treatment Market, Geographical Analysis, 2023
  • 6.2. Global Pulmonary Arterial Hypertension Treatment, Market Attractiveness Analysis, 2024-2030

7. Global Pulmonary Arterial Hypertension Treatment Market Overview

  • 7.1. Market Size & Forecast, 2019-2030
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
      • 7.2.1.1. Endothelin Receptor Antagonists (ERAs)
      • 7.2.1.2. Phosphodiesterase-5 (PDE-5) Inhibitors
      • 7.2.1.3. Prostacyclin Analogues
      • 7.2.1.4. Soluble Guanylate Cyclase Stimulators
      • 7.2.1.5. Others
    • 7.2.2. By Route of Administration
      • 7.2.2.1. Oral
      • 7.2.2.2. Intravenous
      • 7.2.2.3. Subcutaneous
      • 7.2.2.4. Inhalation
    • 7.2.3. By Distribution Channel
      • 7.2.3.1. Hospital Pharmacies
      • 7.2.3.2. Retail Pharmacies
      • 7.2.3.3. Online Pharmacies
    • 7.2.4. By Region
      • 7.2.4.1. North America
      • 7.2.4.2. Europe
      • 7.2.4.3. Asia Pacific (APAC)
      • 7.2.4.4. Latin America (LATAM)
      • 7.2.4.5. Middle East and Africa (MEA)

8. North America Pulmonary Arterial Hypertension Treatment Market

  • 8.1. Market Size & Forecast, 2019-2030
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. United States
      • 8.2.4.1.1. By Drug Type
      • 8.2.4.1.2. By Route of Administration
      • 8.2.4.1.3. By Distribution Channel
      • 8.2.4.2. Canada
      • 8.2.4.2.1. By Drug Type
      • 8.2.4.2.2. By Route of Administration
      • 8.2.4.2.3. By Distribution Channel

9. Europe Pulmonary Arterial Hypertension Treatment Market

  • 9.1. Market Size & Forecast, 2019-2030
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. Germany
      • 9.2.4.1.1. By Drug Type
      • 9.2.4.1.2. By Route of Administration
      • 9.2.4.1.3. By Distribution Channel
      • 9.2.4.2. United Kingdom
      • 9.2.4.2.1. By Drug Type
      • 9.2.4.2.2. By Route of Administration
      • 9.2.4.2.3. By Distribution Channel
      • 9.2.4.3. Italy
      • 9.2.4.3.1. By Drug Type
      • 9.2.4.3.2. By Route of Administration
      • 9.2.4.3.3. By Distribution Channel
      • 9.2.4.4. France
      • 9.2.4.4.1. By Drug Type
      • 9.2.4.4.2. By Route of Administration
      • 9.2.4.4.3. By Distribution Channel
      • 9.2.4.5. Spain
      • 9.2.4.5.1. By Drug Type
      • 9.2.4.5.2. By Route of Administration
      • 9.2.4.5.3. By Distribution Channel
      • 9.2.4.6. Belgium
      • 9.2.4.6.1. By Drug Type
      • 9.2.4.6.2. By Route of Administration
      • 9.2.4.6.3. By Distribution Channel
      • 9.2.4.7. Russia
      • 9.2.4.7.1. By Drug Type
      • 9.2.4.7.2. By Route of Administration
      • 9.2.4.7.3. By Distribution Channel
      • 9.2.4.8. The Netherlands
      • 9.2.4.8.1. By Drug Type
      • 9.2.4.8.2. By Route of Administration
      • 9.2.4.8.3. By Distribution Channel
      • 9.2.4.9. Rest of Europe
      • 9.2.4.9.1. By Drug Type
      • 9.2.4.9.2. By Route of Administration
      • 9.2.4.9.3. By Distribution Channel

10. Asia Pacific Pulmonary Arterial Hypertension Treatment Market

  • 10.1. Market Size & Forecast, 2019-2030
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
      • 10.2.4.1. China
      • 10.2.4.1.1. By Drug Type
      • 10.2.4.1.2. By Route of Administration
      • 10.2.4.1.3. By Distribution Channel
      • 10.2.4.2. India
      • 10.2.4.2.1. By Drug Type
      • 10.2.4.2.2. By Route of Administration
      • 10.2.4.2.3. By Distribution Channel
      • 10.2.4.3. Japan
      • 10.2.4.3.1. By Drug Type
      • 10.2.4.3.2. By Route of Administration
      • 10.2.4.3.3. By Distribution Channel
      • 10.2.4.4. South Korea
      • 10.2.4.4.1. By Drug Type
      • 10.2.4.4.2. By Route of Administration
      • 10.2.4.4.3. By Distribution Channel
      • 10.2.4.5. Australia & New Zealand
      • 10.2.4.5.1. By Drug Type
      • 10.2.4.5.2. By Route of Administration
      • 10.2.4.5.3. By Distribution Channel
      • 10.2.4.6. Indonesia
      • 10.2.4.6.1. By Drug Type
      • 10.2.4.6.2. By Route of Administration
      • 10.2.4.6.3. By Distribution Channel
      • 10.2.4.7. Malaysia
      • 10.2.4.7.1. By Drug Type
      • 10.2.4.7.2. By Route of Administration
      • 10.2.4.7.3. By Distribution Channel
      • 10.2.4.8. Singapore
      • 10.2.4.8.1. By Drug Type
      • 10.2.4.8.2. By Route of Administration
      • 10.2.4.8.3. By Distribution Channel
      • 10.2.4.9. Vietnam
      • 10.2.4.9.1. By Drug Type
      • 10.2.4.9.2. By Route of Administration
      • 10.2.4.9.3. By Distribution Channel
      • 10.2.4.10. Rest of APAC
      • 10.2.4.10.1. By Drug Type
      • 10.2.4.10.2. By Route of Administration
      • 10.2.4.10.3. By Distribution Channel

11. Latin America Pulmonary Arterial Hypertension Treatment Market

  • 11.1. Market Size & Forecast, 2019-2030
    • 11.1.1. By Value (USD Billion)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Type
    • 11.2.2. By Route of Administration
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
      • 11.2.4.1. Brazil
      • 11.2.4.1.1. By Drug Type
      • 11.2.4.1.2. By Route of Administration
      • 11.2.4.1.3. By Distribution Channel
      • 11.2.4.2. Mexico
      • 11.2.4.2.1. By Drug Type
      • 11.2.4.2.2. By Route of Administration
      • 11.2.4.2.3. By Distribution Channel
      • 11.2.4.3. Argentina
      • 11.2.4.3.1. By Drug Type
      • 11.2.4.3.2. By Route of Administration
      • 11.2.4.3.3. By Distribution Channel
      • 11.2.4.4. Peru
      • 11.2.4.4.1. By Drug Type
      • 11.2.4.4.2. By Route of Administration
      • 11.2.4.4.3. By Distribution Channel
      • 11.2.4.5. Rest of LATAM
      • 11.2.4.5.1. By Drug Type
      • 11.2.4.5.2. By Route of Administration
      • 11.2.4.5.3. By Distribution Channel

12. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market

  • 12.1. Market Size & Forecast, 2019-2030
    • 12.1.1. By Value (USD Billion)
  • 12.2. Market Share & Forecast
    • 12.2.1. By Drug Type
    • 12.2.2. By Route of Administration
    • 12.2.3. By Distribution Channel
    • 12.2.4. By Country
      • 12.2.4.1. Saudi Arabia
      • 12.2.4.1.1. By Drug Type
      • 12.2.4.1.2. By Route of Administration
      • 12.2.4.1.3. By Distribution Channel
      • 12.2.4.2. UAE
      • 12.2.4.2.1. By Drug Type
      • 12.2.4.2.2. By Route of Administration
      • 12.2.4.2.3. By Distribution Channel
      • 12.2.4.3. Qatar
      • 12.2.4.3.1. By Drug Type
      • 12.2.4.3.2. By Route of Administration
      • 12.2.4.3.3. By Distribution Channel
      • 12.2.4.4. Kuwait
      • 12.2.4.4.1. By Drug Type
      • 12.2.4.4.2. By Route of Administration
      • 12.2.4.4.3. By Distribution Channel
      • 12.2.4.5. South Africa
      • 12.2.4.5.1. By Drug Type
      • 12.2.4.5.2. By Route of Administration
      • 12.2.4.5.3. By Distribution Channel
      • 12.2.4.6. Nigeria
      • 12.2.4.6.1. By Drug Type
      • 12.2.4.6.2. By Route of Administration
      • 12.2.4.6.3. By Distribution Channel
      • 12.2.4.7. Algeria
      • 12.2.4.7.1. By Drug Type
      • 12.2.4.7.2. By Route of Administration
      • 12.2.4.7.3. By Distribution Channel
      • 12.2.4.8. Rest of MEA
      • 12.2.4.8.1. By Drug Type
      • 12.2.4.8.2. By Route of Administration
      • 12.2.4.8.3. By Distribution Channel

13. Competitive Landscape

  • 13.1. List of Key Players and Their Offerings
  • 13.2. Global Pulmonary Arterial Hypertension Treatment Company Market Share Analysis, 2023
  • 13.3. Competitive Benchmarking, By Operating Parameters
  • 13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

14. Impact of Escalating Geopolitical Tensions on Global Pulmonary Arterial Hypertension Treatment Market

15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 15.1. United Therapeutics Ltd
  • 15.2. Bayer AG
  • 15.3. Actelion Ltd
  • 15.4. Pfizer, Inc.
  • 15.5. Gilead Sciences, Inc.
  • 15.6. GlaxoSmithKline plc
  • 15.7. Teva Pharmaceuticals Inc.
  • 15.8. Eli Lilly and Company
  • 15.9. Steady Med Ltd
  • 15.10. Viatris Inc.
  • 15.11. Sandoz Inc.
  • 15.12. Lupin Pharmaceuticals, Inc.
  • 15.13. Sun Pharmaceutical Industries, Inc.
  • 15.14. Johnson & Johnson
  • 15.15. Other Prominent Players

16. Key Strategic Recommendations

17. Research Methodology

  • 17.1. Qualitative Research
    • 17.1.1. Primary & Secondary Research
  • 17.2. Quantitative Research
  • 17.3. Market Breakdown & Data Triangulation
    • 17.3.1. Secondary Research
    • 17.3.2. Primary Research
  • 17.4. Breakdown of Primary Research Respondents, By Region
  • 17.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable